| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6001861 | BOEHRINGER INGELHEIM | Use of pramipexole in the treatment of restless legs syndrome |
Jan, 2018
(6 years ago) | |
| US6194445 | BOEHRINGER INGELHEIM | Use of pramipexole in the treatment of restless legs syndrome |
Jan, 2018
(6 years ago) | |
Mirapex is owned by Boehringer Ingelheim.
Mirapex contains Pramipexole Dihydrochloride.
Mirapex has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Mirapex are:
- US6001861
- US6194445
Mirapex was authorised for market use on 01 July, 1997.
Mirapex is available in tablet;oral dosage forms.
Mirapex can be used as treatment of moderate to severe primary restless legs syndrome (rls).
The generics of Mirapex are possible to be released after 16 January, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-104) | May 13, 2014 |
Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 01 July, 1997
Treatment: Treatment of moderate to severe primary restless legs syndrome (rls)
Dosage: TABLET;ORAL
How can I launch a generic of MIRAPEX before it's drug patent expiration?
More Information on Dosage
MIRAPEX family patents
